BioNTech shares fell 6.94% to $103.68 Friday after BioNTech and Genentech terminated the Phase 2 BNT122-01 study of autogene cevumeran, a personalized mRNA cancer treatment, in high-risk colorectal cancer. The trial tested the therapy alone in patients whose tumors had been surgically removed but who still had circulating tumor DNA, comparing it with standard monitoring. The study had crossed a futility threshold in October 2025, but independent safety monitors initially considered the data too immature for a firm conclusion. A later review identified an overall-survival gap between treated and untreated patients and concluded that continuing the study would not meaningfully change the outcome. BioNTech Co-Founder and Chief Medical Officer Özlem Türeci called the result disappointing but said it would provide insight into immune-resistant tumors and inform future mRNA oncology research. BioNTech plans further analysis and a later public release of the results. Its separate IMcode003 pancreatic cancer trial, which combines autogene cevumeran with checkpoint inhibitors and chemotherapy, remains unaffected. The colorectal cancer decision follows the discontinuation of a bladder cancer study in March and contrasts with positive Phase 3 melanoma-vaccine results reported by Moderna and Merck alongside Keytruda. BioNTech reported €16.6 billion in cash reserves and marketable securities in Q2 2026, despite a quarterly net loss of €820.8 million, while investors are also watching the ESMO Congress in October 2026 and an interim readout from the BNT113 head and neck cancer program.